Fulcrum Therapeutics, Inc. is discontinuing the development of pociredir, its drug candidate for sickle cell disease [1, 2, 3].
The decision follows safety concerns raised by the U.S. Food and Drug Administration regarding the risk of cancer associated with the treatment [1, 3]. Because pociredir was the company's primary drug program, the halt leaves the Cambridge, Massachusetts-based firm without a lead clinical candidate [1, 4].
Fulcrum announced the discontinuation on June 1, 2026 [1, 5]. Following the announcement, the company's stock price experienced a 51.1% drop on Tuesday, June 2, 2026 [4, 6].
In response to the setback, the company said it has initiated a comprehensive strategic review of alternatives [1, 2, 3]. This review is intended to determine the future direction of the firm, and how it will utilize its remaining resources after the loss of its main program [2, 3].
Sickle cell disease is a genetic blood disorder that causes red blood cells to become misshapen, leading to severe pain and organ damage. The failure of pociredir removes one potential therapeutic option from the current development pipeline for patients seeking new treatments [1, 3].
“The company is discontinuing its sickle cell disease drug candidate pociredir.”
The abrupt termination of pociredir represents a critical failure for Fulcrum Therapeutics, as the drug was the centerpiece of its portfolio. The massive stock decline reflects investor concern over the company's viability without a lead asset. The upcoming strategic review will determine if the company can pivot to a new therapeutic area or if it will seek a merger or acquisition to survive.
